ReviewInternational journal of nanomedicine2026
MicroRNA-26 Family in Human Diseases: Context-Dependent Regulation, Biomarker Potential, and Preclinical Nano-Delivery Strategies.
Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This review aims to summarize the expression patterns, molecular mechanisms, and preclinical nanodelivery strategies of microRNA-26 (miR-26) family members, and to critically evaluate their potential as biomarker candidates and preclinical therapeutic targets in human diseases, including cancers, cardiovascular diseases, metabolic disorders, and neurodegenerative conditions. Methods: A structured narrative review was performed in PubMed, Web of Science, Scopus, and Google Scholar from database inception to August 2026. Peer-reviewed original articles and reviews in English were included. Data on miR-26 isoform expression, target genes, signaling pathways, therapeutic modulators, and nanocarrier systems were extracted and narratively synthesized. A four-tier evidence classification system (Levels I-IV) was applied to distinguish well-established findings from speculative or inferred associations. Results: miR-26 family members-predominantly miR-26a-5p and miR-26b-5p-are highly conserved small non-coding RNAs that post-transcriptionally regulate proliferation, differentiation, apoptosis, metabolism, and immunity in an isoform-specific and context-dependent manner. In most solid tumors, miR-26a-5p and miR-26b-5p are downregulated and function as tumor suppressors, although context-dependent oncogenic roles exist. Circulating and tissue miR-26 isoform levels show statistically significant associations with diagnosis, prognosis, and treatment response in several cancers, supporting their utility as biomarker candidates. However, direct miR-26 mimics or inhibitors remain exclusively preclinical, with no human clinical trials initiated to date. Lipid-, polymer-, and inorganic-based nanocarriers are being explored in preclinical models, but their precision, safety, and biodistribution require systematic validation. Clinical-stage agents targeting downstream effectors of miR-26-regulated pathways do not constitute direct miR-26 modulation and should not be presented as miR-26 therapeutics. Conclusion: miR-26 family members serve as versatile regulatory hubs and biologically plausible biomarker and preclinical therapeutic target candidates. At present, miR-26 should be viewed primarily as a validated biomarker associate and a promising preclinical target-not as an established therapeutic modality. CRISPRa, microbiome-miR-26 interactions, and AI-assisted nanorobots remain future hypotheses rather than established translational strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.